PMID- 35876484
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20220928
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 21
IP  - 9
DP  - 2022 Sep
TI  - Single and combined 1064 nm Q-switched Nd: YAG laser therapy in melasma: A 
      meta-analysis.
PG  - 3794-3802
LID - 10.1111/jocd.15270 [doi]
AB  - PURPOSE: This article attempted to describe the efficacy and safety of 1064QNYL 
      in combination with other treatments for refractory melasma. METHODS: Two 
      researchers independently retrieved randomized controlled trials (RCTs) according 
      to inclusion and exclusion criteria. Primary outcome was evaluated with MASI and 
      mMASI scores in control group and experiment group. The secondary outcome was 
      evaluated with MI scores. We calculated 95% CI of standardized mean difference 
      (SMD) and heterogeneity of the included literature by Higgins I(2) test, and 
      assessed publication bias by Funnel plots, Egger's, and Begg's tests. RESULTS: A 
      total of 12 articles including 322 subjects were analyzed. Experiment group was 
      treated with 1064QNYL combined with single treatment (e.g., PDL, IPL, RF, and 
      TA). Control group was treated with 1064QNYL alone. A greater reduction of 
      Melasma Area and Severity Index (MASI)/modified Melasma Area and Severity Index 
      (mMASI) scores were shown in experiment group than that in control group at the 
      end of the treatment (SMD, -0.37; 95% CI -0.70 to -0.04, p = 0.03, I(2)  = 33%). 
      The SMD of MI scores further supported this conclusion by -0.32 (95% CI -0.63 to 
      -0.02, p = 0.04, I(2)  = 27%). As for adverse events (AEs), combined treatment 
      gave rise to more mild burning, stinging, and erythema that resolved 
      spontaneously. Several studies reported focal purpura, punctate leukoderma, 
      hyperpigmentation, hypopigmentation, and so on. CONCLUSION: Combined 1064QNYL 
      treatment was better than single laser treatment, with the highest short-term 
      benefit and long-term follow-up to maintain the effect in favor of combined 
      treatment.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Zhang, Beilei
AU  - Zhang B
AUID- ORCID: 0000-0002-4297-7392
AD  - The Fourth Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Xie, Bo
AU  - Xie B
AUID- ORCID: 0000-0001-9374-863X
AD  - Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, 
      China.
AD  - Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
AD  - Affiliated Hangzhou Dermatology Hospital, Zhejiang University School of Medicine, 
      Hangzhou, Zhejiang, China.
FAU - Shen, Yuqing
AU  - Shen Y
AD  - Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - The Fourth Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
FAU - Song, Xiuzu
AU  - Song X
AD  - Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, 
      China.
AD  - Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China.
AD  - Affiliated Hangzhou Dermatology Hospital, Zhejiang University School of Medicine, 
      Hangzhou, Zhejiang, China.
LA  - eng
GR  - 81872517/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220905
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
SB  - IM
MH  - Humans
MH  - *Hyperpigmentation/etiology
MH  - *Hypopigmentation/etiology
MH  - *Laser Therapy/adverse effects
MH  - *Lasers, Solid-State/adverse effects
MH  - *Low-Level Light Therapy/adverse effects
MH  - *Melanosis/etiology/radiotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - 1064 nm laser
OT  - Q-Switched Lasers
OT  - combined therapy
OT  - melasma
OT  - meta-analysis
EDAT- 2022/07/26 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/07/25 08:52
PHST- 2022/04/07 00:00 [received]
PHST- 2022/07/21 00:00 [accepted]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/07/25 08:52 [entrez]
AID - 10.1111/jocd.15270 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2022 Sep;21(9):3794-3802. doi: 10.1111/jocd.15270. Epub 2022 
      Sep 5.